SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SWOG | S1803-MM, Maintenance, Len vs Len/Dara | 1 | N | 0 Screening | 1420 | 1448 | 148 | 0 | 0 | 0 | 0 | 08/13/2019 | 30 | 6 |
1448 | 148 | 0 | 0 | 0 | 0 | |||||||||
2 | Y | 1 Lenalidomide | 674 | 77 | 9 | 1 | 0 | 0 | 08/13/2019 | |||||
2 Lenalidomide + Daratumumab | 664 | 74 | 11 | 2 | 0 | 0 | ||||||||
1338 | 151 | 20 | 3 | 0 | 0 | |||||||||
3 | Y | 3 Stop vs Continue Treatment | 275 | 80 | 42 | 9 | 1 | 0 | 08/13/2019 | |||||
275 | 80 | 42 | 9 | 1 | 0 | |||||||||
S2005-WM, Prev. Untreated, I/R +/- Venetoclax | 1 | Y | 1 I+R | 92 | 8 | 7 | 2 | 1 | 0 | 0 | 01/05/2022 | 109 | 28 | |
2 I+R+Venetoclax | 1 | 0 | 0 | 0 | 0 | 0 | ||||||||
3 V+R | 7 | 4 | 2 | 1 | 1 | 0 | ||||||||
16 | 11 | 4 | 2 | 1 | 0 | |||||||||
S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D | 1 | Y | 1 VRD-R | 510 | 30 | 20 | 9 | 2 | 1 | 0 | 10/12/2023 | 258 | 82 | |
2 DRD-R | 31 | 19 | 9 | 5 | 1 | 0 | ||||||||
3 DRD-DR | 28 | 18 | 8 | 3 | 2 | 0 | ||||||||
89 | 57 | 26 | 10 | 4 | 0 | |||||||||
S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT | 1 | Y | 0 Induction | 338 | 19 | 18 | 10 | 8 | 5 | 1 | 07/01/2024 | 149 | 44 | |
19 | 18 | 10 | 8 | 5 | 1 | |||||||||
2 | Y | 1 Dara-VCD | 4 | 4 | 3 | 1 | 0 | 0 | 07/01/2024 | |||||
2 Melphalan + ASCT | 4 | 4 | 2 | 2 | 0 | 0 | ||||||||
8 | 8 | 5 | 3 | 0 | 0 | |||||||||
3 | Y | 3 Dara | 2 | 2 | 2 | 1 | 1 | 0 | 07/01/2024 | |||||
2 | 2 | 2 | 1 | 1 | 0 | |||||||||
Yes | EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) | 0 | E | Total Registrations | 59 | 13 | 8 | 5 | 2 | 0 | 05/27/2021 | 229 | 80 | |
59 | 13 | 8 | 5 | 2 | 0 | |||||||||
1 | E | Total Registrations | 43 | 8 | 6 | 4 | 1 | 0 | 05/27/2021 | |||||
43 | 8 | 6 | 4 | 1 | 0 | |||||||||
2 | E | Total Registrations | 31 | 9 | 2 | 2 | 0 | 0 | 05/27/2021 | |||||
31 | 9 | 2 | 2 | 0 | 0 | |||||||||
No | EAA173-MYEL, SMM, Rd +/- Daratumumab | 0 | E | Total Registrations | 78 | 7 | 3 | 3 | 0 | 0 | 01/08/2020 | 251 | 100 | |
78 | 7 | 3 | 3 | 0 | 0 | |||||||||
1 | E | Total Registrations | 38 | 6 | 1 | 1 | 0 | 0 | 01/08/2020 | |||||
38 | 6 | 1 | 1 | 0 | 0 | |||||||||
Study | Registration/Phase | Open Date | # of ACT. INSTs |
# of CURR IRBs |
---|---|---|---|---|
S2005 WM, Prev. Untreated, I/R +/- Venetoclax | 2 Crossover | 24-Jun-21 | 109 | 28 |